Botanical species · safety record

Hebanthe eriantha

The EFSA Compendium of Botanicals holds 13 constituent measurements, 1 adverse-effect record and 1 genotoxicity assay for Hebanthe eriantha. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Hebanthe eriantha (Poir.) Pedersen

13Constituent measurements

2Safety records

8Cited sources

62Licensed products (Canada)

Also recorded as

Pfaffia pulverulenta (Mart.) Kuntze
Hebanthe pulverulenta Mart.
Hebanthe paniculata Mart.
Gomphrena paniculata (Mart.) Moq.
Pfaffia paniculata (Mart.) Kuntze

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 62 licensed products naming Hebanthe eriantha as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
Extract Type TBA

Source material stated

Hebanthe eriantha - Root
New material
Plante entière
Root
Root (powder)
Root extract

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Oleanolic saponins	Roots and other underground parts	Solvent extraction	—	HPLC with standard detection methods	Resolve DOI
Pentacyclic triterpenic derivatives	Roots and other underground parts	Solvent extraction	—	HPLC with standard detection methods	Resolve DOI
Pfaffic acid	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Pfaffosides	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Pfaffosides	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Pentacyclic triterpene glycosides	Roots and other underground parts	Solvent extraction	—	Colorimetry, Spectroscopy (Spectrometry) and Photometry	No resolvable identifier
Pfaffic acid	Roots and other underground parts	Solvent extraction	≤ 0.64 Percent	HPLC-DAD	No resolvable identifier
Pfaffic acid	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Pfaffic acid	Roots and other underground parts	Solvent extraction	≥ 0.37 Percent	HPLC-DAD	No resolvable identifier
Saponins	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Saponins	Roots and other underground parts	Solvent extraction	—	Traditional analytical techniques (wet chemical tests)	No resolvable identifier
Saponins	Roots and other underground parts	—	≥ 4 Percent	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Saponins	Roots and other underground parts	—	≤ 11.1 Percent	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Endocrine	—	Roots and other underground parts	Powder	House mouse (as animal)	Reproduction toxicity	No resolvable identifier

Genotoxicity testing

Outcomes of genotoxicity assays as recorded in the source. A negative assay is a result under those test conditions, not a clearance.

Outcome	Endpoint	Test	Tested organism	Metabolic activation	Source
Positive	gene mutation	bacterial gene mutation assay	Salmonella typhimurium (as organism)	With and without	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

NISHIMOTO, N., NAKAI, S., TAKAGI, N., HAYASHI, S., TAKEMOTO, T., ODASHIMA, S., KIZU, H., WADA, Y. PFAFFOSIDES AND NORTRITERPENOID SAPONINS FROM PFAFFIA-PANICULATA. Phytochemistry, 1984, vol. 23, no. 1, p. 139-142. DOI
Oshima, M., Gu, Y. Pfaffia paniculata-induced changes in plasma estradiol-17 beta, progesterone and testosterone levels in mice . Journal of reproduction and development, 2003, vol. 49, no. 2, p. 175-180.
Vilela, Gisele F., Ming, Lin C., Marques, Marcia O. M., da Silva, Sandra M. P., Montanari Junior, Ilio. Agronomical and phytochemical aspects of fafia. Horticultura brasileira, 2013, vol. 31, no. 1, p. 133-138.
De Oliveira, Fernando., Akisue, Gokithi., Akisue, Maria Kubata. Contribution to the pharmacognostic study of Brazilian ginseng Pfaffia paniculata (Martius) Kuntze. Anais de farmacia e quimica de sao paulo, 1980, vol. 20(1-2), p. 261-77.
RIVERA, IG., MARTINS, MT., SANCHEZ, PS., SATO, MIZ., COELHO, MCL., AKISUE, M., AKISUE, G. GENOTOXICITY ASSESSMENT THROUGH THE AMES TEST OF MEDICINAL-PLANTS COMMONLY USED IN BRAZIL . Environmental toxicology and water quality, 1994, vol. 9, no. 2, p. 87-93. DOI
Gao, H., Ma, X.-J., Wen, X.-S., Chen, D.-H., Si, J.-Y. Chemical constituents from Pfaffia paniculata. Chinese traditional and herbal drugs, 2009, vol. 40, no. 4, p. 522-525.
NAKAI, S., TAKAGI, N., MIICHI, H., HAYASHI, S., NISHIMOTO, N., TAKEMOTO, T., KIZU, H. PFAFFOSIDES .2. PFAFFOSIDES, NORTRITERPENOID SAPONINS, FROM PFAFFIA-PANICULATA . Phytochemistry, 1984, vol. 23, no. 8, p. 1703-1705. DOI
Li, Jing., Jadhav, Atul N., Khan, Ikhlas A. Triterpenoids from Brazilian Ginseng, Pfaffia paniculata. Planta medica, 2010, vol. 76, no. 6, p. 635-639. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature